<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684032</url>
  </required_header>
  <id_info>
    <org_study_id>B2151009</org_study_id>
    <nct_id>NCT02684032</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer</brief_title>
  <official_title>Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (Mbc)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have
      a dose escalation to identify the maximum tolerated dose (MTD) of the combination of
      gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and
      expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus
      palbociclib/letrozole or palbociclib/fulvestrant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, continuous Phase 1b study in patients with MBC. This study
      will have a dose escalation and expansion. The dose escalation will identify the maximum
      tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and
      gedatolisib plus palbociclib/letrozole. The expansion will estimate the objective response
      rate (OR) of the combination of gedatolisib plus palbociclib/letrozole and the combination of
      gedatolisib plus palbociclib/fulvestrant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Anticipated">November 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate observed in patients in the dose expansion portion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients for each response category, objective response rate (number of patients with a complete response (CR)) relative to the number of response evaluable patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate observed in patients in the dose expansion portion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients for each response category, objective response rate (number of patients with a partial response (PR)) relative to the number of response evaluable patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response observed in patients in the dose escalation portion</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval (corrected QT interval)</measure>
    <time_frame>Screening up to 6 months</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Day 1: 0, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 24, 72 and 168 hours. Cycle 2 Day 1: 0, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 24, 72 and 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole combination cohort in dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant combination cohort in dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + letrozole in dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + fulvestrant in dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + fulvestrant in dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gedatolisib</intervention_name>
    <description>Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.</description>
    <arm_group_label>Letrozole Cohort</arm_group_label>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.</description>
    <arm_group_label>Letrozole Cohort</arm_group_label>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole at 2.5 mg daily</description>
    <arm_group_label>Letrozole Cohort</arm_group_label>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.</description>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women 18 years of age or older, who are either: Postmenopausal or Pre/perimenopausal
             women with medically-induced menopause by treatment with agents to induce chemical
             menopause.

          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of
             metastasis.

          -  Documentation of estrogen receptor positive ((ER+), human epidermal growth factor
             receptor 2 (HER2 negative (HER2-)) tumor.

          -  Dose Escalation Portion: Patients must satisfy one of the following criteria:

               -  Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression
                  who are candidates for a letrozole-containing regimen, with palbociclib.

               -  Fulvestrant combination cohort (F): MBC with progression who are candidates for a
                  fulvestrant containing regimen, with palbociclib.

          -  Dose Expansion Portion: Patients must satisfy one of the following criteria:

               -  Arm A: MBC with progression and no prior endocrine based systemic therapy in the
                  metastatic setting;

               -  Arm B: MBC with progression during or following one prior endocrine based
                  systemic therapy in the metastatic setting, with no prior therapy with any
                  cyclin-dependent kinase (CDK) inhibitor;

               -  Arm C: MBC with progression during or following one or two prior endocrine based
                  systemic therapies in the metastatic setting, and following prior therapy with a
                  CDK inhibitor.

          -  Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST)
             version 1.1.

          -  Bone only patients during dose escalation portion.

          -  Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not
             available.

          -  Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.

          -  Adequate bone marrow, renal and liver function.

        Exclusion Criteria:

          -  Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or
             phosphoinositide 3-kinase (PI3K) inhibitor.

          -  More than 1 line of prior chemotherapy in the treatment of metastatic or locally
             advanced/recurrent disease.

          -  Bone only patients during expansion/efficacy portion.

          -  Patients with advanced/metastatic disease who have symptomatic visceral spread, and
             who have life threatening complications needing immediate therapy, such as massive
             uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and
             over 50% liver replacement with tumor.

          -  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.

          -  Active bacterial, fungal or viral infection.

          -  Uncontrolled or significant cardiovascular disease.

          -  Radiation therapy within 4 weeks of investigational product.

          -  Cytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for
             mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3
             4 week schedule or 2 weeks of investigational product if immediate prior regimen
             consisted of weekly therapy.

          -  Any other anti cancer agents (eg, hormonal, biological, investigational) within 5
             times the half life prior to investigational product.

          -  Impairment of gastro intestinal (GI) function or GI disease.

          -  Pregnant female patients; breastfeeding female patients; and female patients of
             childbearing potential who are unwilling or unable to use 2 highly effective methods
             of contraception as outlined in this protocol for the duration of the study and for 90
             days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center / Investigational Drug Services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRUG SHIPMENT: ATTN: Research Pharmacist</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Inpatient Pavillion (AIP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Outpatient Pavilllion (AOP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Clinical Trials Office (CTO)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital- Anschutz Caner Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt McKinley Outpatient Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Insutitute - Investigation Pharmacy</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Healthcare, NC Cancer Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals, The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephanie Spielman Comprehensive Breast Cancer</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Health Pharmacy One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.T. MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2151009&amp;StudyName=Phase%201b%20Study%20To%20Assess%20The%20Safety%2C%20Tolerability%2C%20And%20Clinical%20Activity%20Of%20Gedatolisib%20In%20Combination%20With%20Palbociclib%20And%20Either%20Letrozole%20Or%20Fulvestrant%20In%20Women%20With%20Metastatic%20Or%20Locally%20Advanced%2Frecurrent%20Breast%20Cancer%20%28mbc%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2151009&amp;StudyName=Phase+1b+Study+To+Assess+The+Safety%2C+Tolerability%2C+And+Clinical+Activity+Of+Gedatolisib+In+Combination+With+Palbociclib+And+Either+Letrozole+Or+Fulvestrant+In+Women+With+Metastatic+Or+Locally+Advanced%2Frecurrent+Breast+Cancer+%28mbc%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K (phosphoinositide 3-kinase)</keyword>
  <keyword>mTOR (mechanistic target of rapamycin)</keyword>
  <keyword>PI3K/mTOR</keyword>
  <keyword>metastatic breast cancer (MBC)</keyword>
  <keyword>ER+ (estrogen receptor positive)</keyword>
  <keyword>HER2- (human epidermal growth factor receptor 2 negative)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

